ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additiona...
22 März 2021 - 9:05PM
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage
biotechnology company focused on discovering and developing direct
lytic agents for the treatment of life-threatening infectious
diseases, today announced the closing of an underwritten public
offering of 11,500,000 shares of its common stock at a public
offering price of $5.00 per share, including 1,500,000 shares sold
pursuant to the underwriters’ exercise in full of their option to
purchase additional shares. The gross proceeds from the public
offering were $57.5 million, before deducting underwriting
discounts and commissions and offering expenses payable by
ContraFect. All shares in the offering were sold by ContraFect.
SVB Leerink and Cantor acted as joint
bookrunning managers for the offering. Mizuho Securities acted as a
passive bookrunning manager for the offering. Maxim Group LLC acted
as a co-manager for the offering.
The offering was made pursuant to an effective
shelf registration statement on Form S-3 that was filed with the
U.S. Securities and Exchange Commission (SEC) on August 14, 2020
and declared effective on August 31, 2020. A final prospectus
supplement was filed with the SEC and forms a part of the effective
registration statement. Copies of the final prospectus supplement
and accompanying prospectus relating to the offering may be
obtained by contacting SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, Massachusetts
01220, by email at syndicate@svbleerink.com, or by telephone at
(800) 808-7525, ext. 6105; or Cantor Fitzgerald & Co., Attn:
Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022;
Email: prospectus@cantor.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities, in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
Investor Relations Contact
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Carlo Tanzi, Ph.D.Kendall Investor RelationsEmail:
ctanzi@kendallir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024